Quick Facts / Company Snapshot
| Metric | Value |
| Company Name | Donaldson Company, Inc. |
| Ticker Symbol | DCI |
| Stock Exchange | New York Stock Exchange |
| Year Founded | 1915 |
| Headquarters | 1400 West 94th Street, Bloomington, Minnesota 55431 |
| Chairman, President, and CEO | Tod E. Carpenter |
| Total Revenue (Fiscal 2025) | $3,690.9 million |
| Net Earnings (Fiscal 2025) | $367.0 million |
| Diluted Earnings Per Share | $3.05 |
| Gross Margin | 34.8% |
| Operating Margin | 13.4% |
| Total Assets | $2,977.2 million |
| Total Employees | Approximately 15,000 |
| Global Footprint | Over 150 locations on six continents |
| Manufacturing & Distribution | 77 locations globally |
| Largest Revenue Segment | Mobile Solutions ($2,291.0 million) |
| Largest Geographic Market | United States and Canada (44.2% of sales) |
| Research & Development Spend | $87.8 million (2.4% of net sales) |
| Capital Expenditures | $77.0 million |
| Dividend Track Record | Increased for 30 consecutive years |
Company Overview
Donaldson Company, Inc. operates as a global provider of technology-led filtration products and solutions. The enterprise designs and manufactures filtration systems for a diverse array of industries, supplying products to original equipment manufacturers, distributors, and end-users. The organizational framework is built upon materials science expertise, focusing on the protection of sensitive equipment, improving process efficiency, and ensuring sterile environments.
Operations span six continents, supported by a workforce of approximately 15,000 employees. Over half of these employees, representing 58% of the corporate headcount, are dedicated to production-related roles. The operational structure prioritizes technical performance and reliability to deliver value across heavy machinery, aerospace, and biotechnology applications.
- Fiscal 2025 Top-Line Performance: The enterprise generated $3,690.9 million in total sales.
- Manufacturing Density: The supply chain is sustained by 77 specialized manufacturing and distribution centers designed for regional responsiveness.
- Operating Profitability: The organization reported an adjusted operating margin of 15.7% for the fiscal year.
The overarching purpose of the enterprise is to advance filtration for a cleaner world. This objective is underpinned by a recurring revenue business model heavily weighted toward aftermarket operations. Selling proprietary replacement filters to a broad installed base of equipment generates consistent cash flow, offsetting the cyclical pressures typically associated with new capital equipment sales.
Business Segments
The organizational architecture is divided into three primary reporting segments: Mobile Solutions, Industrial Solutions, and Life Sciences. Each segment addresses specific market demands, regulatory environments, and customer profiles.
Mobile Solutions
Revenue: $2,291.0 million | % of Total Revenue: 62.1%
The Mobile Solutions segment represents the highest revenue generator for the enterprise. It is organized into the Aftermarket, Off-Road, and On-Road business units. The segment provides replacement filters for air and liquid filtration applications, alongside filtration housings utilized in new equipment production.
The operational scope encompasses engineered air filtration systems, fuel, lube, and hydraulic systems, as well as emissions systems and sensors. The primary customer base includes OEMs in the construction, mining, agriculture, and transportation end markets, along with independent distributors and expansive OEM dealer networks.
- Aftermarket Revenue: $1,820.9 million, representing 49.3% of total enterprise revenue. This unit experienced a $90.7 million increase driven by market demand and share gains.
- Off-Road Revenue: $359.5 million, representing 9.7% of total enterprise revenue.
- On-Road Revenue: $110.6 million, representing 3.0% of total enterprise revenue.
- Segment Profitability: Pre-tax earnings reached $417.6 million, representing an 18.2% margin on net segment sales.
Industrial Solutions
Revenue: $1,104.4 million | % of Total Revenue: 29.9%
The Industrial Solutions segment delivers a comprehensive product offering designed to enhance productivity and manufacturing efficiency. The segment operates through the Industrial Filtration Solutions and Aerospace and Defense business units. Sales channels are diversified, reaching customers through specialized distributors, direct-to-consumer models, and OEM partnerships.
The product portfolio includes industrial dust, fume, and mist collectors, compressed air and gas purification systems, and specialized hydraulic filtration applications. Additionally, the segment provides air inlet systems engineered for gas compression, power generation, and natural gas liquefaction.
- Industrial Filtration Solutions Revenue: $914.2 million, representing 24.8% of total enterprise revenue. Growth was supported by strength in new equipment installations and replacement part sales.
- Aerospace and Defense Revenue: $190.2 million, representing 5.2% of total enterprise revenue. This unit saw a $24.8 million increase due to ongoing strength in defense spending.
- Segment Profitability: Pre-tax earnings reached $197.7 million, representing a 17.9% margin on net segment sales.
Life Sciences
Revenue: $295.5 million | % of Total Revenue: 8.0%
The Life Sciences segment caters to the Food and Beverage, Disk Drive, Vehicle Electrification, Medical Device, Microelectronics, and Bioprocessing markets. The segment targets large OEMs and end-users requiring solutions for cell growth, viral separation, liquid purification, and sensitive device protection.
Products within this segment include micro-environment gas and liquid filtration, bioprocessing equipment such as bioreactors, and consumables like chromatography devices and reagents. The segment also develops advanced air and gas filtration systems required for semiconductor manufacturing cleanrooms and modern electric vehicle battery systems.
- Segment Growth: Total segment revenue was $295.5 million, reflecting a 9.8% year-over-year increase.
- Growth Drivers: Expansion was driven by market demand in the Disk Drive unit and market share gains within the Food and Beverage sector.
- Segment Profitability: Pre-tax earnings totaled $4.4 million, representing a 1.5% margin on net sales, marking a transition toward segment profitability.
History and Evolution
The enterprise was founded in 1915, initiating a century-long trajectory of technological advancement in the industrial filtration sector. Over the decades, the organization evolved from a localized agricultural operation in the American Midwest to a global presence across multiple technical industries.
The evolution of the enterprise is marked by a deliberate strategy of technological expansion, intellectual property generation, and targeted strategic acquisitions. The company holds a vast intellectual property portfolio comprising over 3,100 issued patents globally.
- Fiscal 2022 Acquisitions: The organization expanded its bioprocessing capabilities by acquiring Solaris Biotechnology S.r.l., a designer of bioreactors and fermenters, and Purilogics LLC, a biotechnology firm focused on membrane chromatography.
- Fiscal 2023 Acquisitions: The enterprise scaled its Life Sciences segment by acquiring Isolere Bio, Inc., a developer of IsoTag™ reagents, and Univercells Technologies, a producer of single-use structured fixed-bed bioreactors.
- Infrastructure Growth: In October 2024, the enterprise launched a new state-of-the-art distribution center in Olive Branch, Mississippi, strengthening its logistical ability to meet demand in the North American aftermarket business.
Products and Services
The product portfolio is diversified and technical, ensuring stability across varying macroeconomic cycles. The products are engineered to safeguard critical capital components, reduce maintenance downtime, and support sustainability metrics.
Air Filtration (Mobile Solutions)
Revenue: $1,365.6 million | % of Total Revenue: 37.0%
Air filtration systems are critical for protecting engine components against abrasive wear caused by dust, silica, and environmental particles. These heavy-duty systems are essential for agricultural tractors, construction excavators, mining machinery, and commercial vehicles.
Industrial Air Filtration (Industrial Solutions)
Revenue: $516.7 million | % of Total Revenue: 14.0%
These systems collect and neutralize dust, fume, and chemical mist within enclosed manufacturing facilities. The portfolio includes cartridge-style and bag house collectors that support industrial customers throughout the equipment lifecycle.
Fuel & Lube (Mobile Solutions)
Revenue: $479.8 million | % of Total Revenue: 13.0%
Fuel and lube systems remove microscopic contaminants that can destroy fuel injectors, valves, and pumps. The product line includes primary and secondary particulate filters, coalescing fuel water separators, and all-in-one filtration systems designed to protect machinery operating under continuous conditions.
Hydraulic (Mobile Solutions)
Revenue: $332.2 million | % of Total Revenue: 9.0%
Hydraulic filtration solutions protect high-pressure fluid power equipment. Applications range from suction strainers to high-pressure filters and atmospheric breather filters. These products ensure contaminant retention, resulting in cleaner oil and reduced pump wear.
Aerospace & Defense (Industrial Solutions)
Revenue: $184.5 million | % of Total Revenue: 5.0%
Designed to protect mission-critical systems from contamination, these filtration products ensure the operation of fixed-wing aircraft, military helicopters, ground defense vehicles, and naval vessels. The portfolio covers engine intake, cabin air purification, and avionics cooling air.
Power Generation (Industrial Solutions)
Revenue: $184.5 million | % of Total Revenue: 5.0%
This category provides leading global OEMs with custom-engineered air intake systems for industrial gas turbines and compressors. The products are utilized in power plants, oil and gas delivery networks, and refining facilities.
Industrial Gases (Industrial Solutions)
Revenue: $147.6 million | % of Total Revenue: 4.0%
Industrial gas solutions address purification objectives using premium filtration and desiccant drying products. The category includes dust collectors for industrial air compressors and air/oil separators utilized within automated manufacturing environments.
Emissions (Mobile Solutions)
Revenue: $110.7 million | % of Total Revenue: 3.0%
This category focuses on sound-reducing mufflers and emission control systems. Key products include diesel particulate filters and catalytic reduction substrates essential for reducing toxic emissions of particulate matter across transportation markets.
Food & Beverage (Life Sciences)
Revenue: $110.7 million | % of Total Revenue: 3.0%
These sanitary solutions guarantee process and product integrity within food and beverage manufacturing. Products include sterile liquid, sterile compressed air, and culinary steam filtration utilized in modern food science.
Other Life Sciences (Life Sciences)
Revenue: $110.7 million | % of Total Revenue: 3.0%
This technical grouping includes Vehicle Electrification, Medical Devices, Microelectronics, and Bioprocessing components. Products range from pressure-equalizing battery vents for electric vehicles to proprietary IsoTag™ chemical reagents utilized in biopharmaceutical manufacturing.
Disk Drive (Life Sciences)
Revenue: $73.8 million | % of Total Revenue: 2.0%
Disk drive products utilize absorbent materials to control moisture and corrosive molecular contaminants in sealed microenvironments. These filters protect delicate internal components necessary for global cloud computing servers and data storage centers.
Industrial Hydraulics (Industrial Solutions)
Revenue: $73.8 million | % of Total Revenue: 2.0%
Industrial hydraulic products solve high-temperature contamination challenges within environments like steel mills, paper mills, and heavy refineries. These filtration products protect vulnerable system components from abrasive wear metals and emulsified water.
Brand Portfolio
The enterprise owns a valuable portfolio of trademarks and proprietary technologies recognized globally for their performance. While specific financial revenue breakdowns per individual brand are not independently disclosed, these technologies are integrated into the products that drive the company’s revenue stream.
- PowerCore®: Filtration technology that surpasses standard pleated cellulose filters in particulate efficiency and physical compactness.
- Ultra-Web®: Proprietary fine-fiber media capable of withstanding the extreme high temperatures and sustained humidity encountered by heavy industrial turbines.
- Ultra-Web® HD: A durable evolution of the core technology ensuring consistent inter-fiber spacing optimized for fine dust environments in surface mining operations.
- Synteq® XP: A multi-layered synthetic media offering higher fuel system protection under dynamic application conditions compared to alternative media.
- Synteq® DRY: Coalescing technology engineered to physically remove emulsified water in real-world operating conditions.
- Duramax®: Spin-on configuration filters that replace costlier legacy housing options in complex hydraulic systems.
- Alpha-Web™: Hydraulic filtration media featuring a fine-fiber layer that dynamically traps and locks particles during frequent flow-rate changes.
- iCue™: Subscription-based Connected Filtration Technology that proactively monitors industrial dust collection equipment via cellular networks.
- IsoTag™: Chemical reagents utilized for the rapid purification and commercial manufacturing of viral vectors used in cell and gene therapies.
- scale-X™: Single-use structured fixed-bed bioreactor designed for the high-density production of viruses utilized in gene therapy.
- NevoLine™: Automated upstream platform incorporating industry-standard filtration to provide integrated processing capabilities.
- Purexa™: Membrane chromatography products engineered for the rapid purification of pDNA, mRNA, and mAbs.
Geographical Presence
The organization manages an optimized, global region-for-region manufacturing and localized distribution footprint. Commercial and industrial operations span across more than 150 administrative and technical locations worldwide.
United States and Canada
Revenue: $1,632.3 million | % of Total Revenue: 44.2%
This mature region serves as the foundational revenue market and global corporate headquarters for the enterprise.
- Infrastructure: The region operates 20 specialized manufacturing plants and 5 high-volume distribution centers.
- Distribution Expansion: In October 2024, the enterprise strengthened this geography by opening a new automated distribution center in Olive Branch, Mississippi.
- Physical Assets: The net carrying value of property, plant, and equipment within this region totals $225.7 million.
Europe, Middle East, and Africa
Revenue: $1,027.2 million | % of Total Revenue: 27.8%
This complex region represents a sophisticated market requiring stringent environmental regulatory compliance and technical product specifications.
- Infrastructure: The enterprise operates 16 manufacturing plants and 2 primary distribution centers within this region.
- Strategic Expansion: The company expanded its technical food and beverage filtration services across France, Germany, and Austria.
- Physical Assets: The net carrying value of property, plant, and equipment in this region totals $195.2 million.
Asia Pacific
Revenue: $635.7 million | % of Total Revenue: 17.2%
This region is a critical growth vector, supporting rapid industrialization, continuous mining operations, and infrastructure development.
- Infrastructure: The region is supported by 11 manufacturing plants and 10 localized distribution centers.
- Physical Assets: The net carrying value of property, plant, and equipment within this region totals $76.2 million.
Latin America
Revenue: $395.7 million | % of Total Revenue: 10.8%
This commodity-driven region supports continental-scale agricultural and deep-earth mining sectors reliant on the company’s heavy-duty mobile solutions.
- Infrastructure: Operations in this territory are sustained by 7 manufacturing plants and 6 localized distribution centers.
- Physical Assets: The net carrying value of property, plant, and equipment in this region totals $147.4 million, representing a significant capital investment relative to its revenue share.
Profit and Loss
The enterprise delivered record financial performance in fiscal 2025, navigating an inflationary global macroeconomic environment through disciplined execution and expense management.
| Profit and Loss Metric (in millions) | Fiscal 2025 | Fiscal 2024 | Change ($) |
| Net Sales | $3,690.9 | $3,586.3 | $104.6 |
| Cost of Sales | $2,404.7 | $2,311.9 | $92.8 |
| Gross Profit | $1,286.2 | $1,274.4 | $11.8 |
| Gross Margin (%) | 34.8% | 35.5% | -0.7% |
| Selling, General & Administrative | $641.0 | $636.7 | $4.3 |
| Loss on Impairment of Assets | $62.0 | $0.0 | $62.0 |
| Research & Development | $87.8 | $93.6 | -$5.8 |
| Operating Income | $495.4 | $544.1 | -$48.7 |
| Operating Margin (%) | 13.4% | 15.2% | -1.8% |
| Interest Expense | $24.2 | $21.4 | $2.8 |
| Other Income, net | $(21.0) | $(12.6) | -$8.4 |
| Earnings Before Income Taxes | $492.2 | $535.3 | -$43.1 |
| Income Taxes | $125.2 | $121.3 | $3.9 |
| Net Earnings | $367.0 | $414.0 | -$47.0 |
| Net Earnings per Share – Diluted | $3.05 | $3.38 | -$0.33 |
- Revenue Growth Drivers: Total net sales increased by 2.9%, driven by a $60.0 million positive impact from sales volume expansion and a $36.3 million benefit from disciplined pricing actions.
- Margin Pressures: The consolidated gross margin experienced a decrease to 34.8%, driven by higher manufacturing costs associated with global footprint optimization initiatives and tariff-related inflation.
- Impairment Charge: A non-cash impairment charge of $62.0 million was recorded during the fiscal year. This write-down reflected lower-than-anticipated bioprocessing capital spending in the broader market, affecting the near-term valuation of the Univercells Technologies and Solaris operating units.
- Effective Tax Rate: The global effective tax rate rose to 25.4% from 22.7%, impacted by the discrete tax effect related to the impairment of intangible assets in the Life Sciences segment.
Balance Sheet
The corporate balance sheet remains highly resilient, supporting capital returns to the shareholder base while funding strategic investments in manufacturing capacity.
| Balance Sheet Metric (in millions) | July 31, 2025 | July 31, 2024 |
| Cash and Cash Equivalents | $180.4 | $232.7 |
| Accounts Receivable, net | $662.2 | $629.7 |
| Inventories, net | $513.6 | $476.7 |
| Total Current Assets | $1,461.7 | $1,438.1 |
| Property, Plant and Equipment, net | $644.5 | $645.5 |
| Goodwill | $493.6 | $478.4 |
| Intangible Assets, net | $97.4 | $171.9 |
| Total Assets | $2,977.2 | $2,914.3 |
| Short-Term Borrowings | $31.2 | $28.3 |
| Accounts Payable | $368.6 | $379.4 |
| Total Current Liabilities | $757.2 | $782.5 |
| Long-Term Debt | $630.4 | $483.4 |
| Total Liabilities | $1,425.2 | $1,523.7 |
| Total Stockholders’ Equity | $1,453.5 | $1,489.1 |
- Working Capital Dynamics: The overall net cash conversion cycle increased to 85 days from 76 days. This shift was influenced by a 4-day increase in days inventory outstanding, rising to 75 days, and a 5-day decrease in days payable outstanding.
- Debt Profile: Total consolidated debt represents 31.5% of total capitalization, marking an increase from 26.5% in the prior fiscal year. This higher leverage was driven by external financing required to fund the equity method investment in Medica.
- Credit Facility Expansion: The enterprise amended its unsecured revolving credit facility. The amendment extended the final maturity to 2030, increased the total borrowing limit to $600.0 million, and added a new $200.0 million term loan facility.
Cash Flow
Predictable free cash flow generation allows the organization to fund global operations while consistently rewarding shareholders through direct capital distribution.
| Cash Flow Metric (in millions) | Fiscal 2025 | Fiscal 2024 | Change ($) |
| Net Cash Provided by Operating Activities | $418.8 | $492.5 | -$73.7 |
| Net Cash Used in Investing Activities | $(150.4) | $(86.9) | -$63.5 |
| Net Cash Used in Financing Activities | $(321.7) | $(355.9) | $34.2 |
| Effect of Exchange Rate Changes | $1.0 | $(4.1) | $5.1 |
| Net (Decrease) Increase in Cash | $(52.3) | $45.6 | -$97.9 |
- Operating Contraction: Operating cash flow decreased due to intentionally higher working capital requirements necessary to support volume growth and the timing of international income tax payments.
- Investing Cash Flow: The increase in investing cash outflows was tied to the $71.2 million equity method investment deployed to secure a stake in Medica.
- Financing Returns: Management directed $331.5 million toward open-market share repurchases and distributed $131.9 million toward scheduled dividend payments during the fiscal year.
Board of Directors and Leadership Team
The enterprise is guided by an experienced executive leadership team and overseen by an independent Board of Directors composed of leading industrial executives.
Executive Leadership Team
- Tod E. Carpenter (Chairman, President and Chief Executive Officer): Appointed as Chief Executive in 2015 and elevated to Chairman in 2017. Carpenter joined the enterprise in 1996 and has an extensive operational background, having previously served as Chief Operating Officer.
- Bradley J. Pogalz (Chief Financial Officer): Appointed to the CFO position in November 2024. Pogalz joined the finance team in 2015, previously serving as Vice President of Finance – Global FP&A and Director of Investor Relations.
- Amy C. Becker (Chief Legal Officer and Corporate Secretary): Appointed in November 2022. Becker has deep institutional knowledge, having joined the organization in 1998.
- Guillermo Briseño (President, Industrial Solutions): Elevated to President in November 2022. Briseño has been active with the company since 2003, driving Latin American operations and global industrial sales strategies.
- Darcy D. DeVincke (Chief Human Resources Officer): Appointed in October 2024. DeVincke initially worked at the company from 2001 to 2008, returning in 2016 to lead global HR initiatives.
- Richard B. Lewis (Chief Operating Officer): Appointed as COO in August 2025. Lewis joined the enterprise in 2002 and has served as President of both the Life Sciences and Mobile Solutions segments.
Board of Directors
- Christopher M. Hilger: Lead Independent Director; Chairman, President, and CEO of Securian Financial Group, Inc.
- Pilar Cruz: Executive VP and Chief Sustainability Officer at Cargill, Inc.
- Douglas A. Milroy: Former Chairman and CEO of G & K Services, Inc.
- Willard D. Oberton: Retired Chairman of Fastenal Company.
- Richard M. Olson: Chairman, President, and CEO of The Toro Company.
- James J. Owens: Retired President and CEO of H.B. Fuller Company.
- Ajita G. Rajendra: Retired Executive Chairman of A.O. Smith Corporation.
- Trudy A. Rautio: Retired President and CEO of Carlson.
- Jacinth C. Smiley: Executive VP and Chief Financial Officer of Hormel Foods.
Subsidiaries, Associates, Joint Ventures
The enterprise utilizes targeted joint ventures and strategic investments to amplify its global market reach and share technological risk.
- Advanced Filtration Systems Inc. (50% Ownership): Established in 1986 as a strategic joint venture with Caterpillar Inc. This entity specializes in designing and manufacturing high-efficiency fluid filters utilized within Caterpillar’s worldwide machinery network. The entity generated equity earnings totaling $12.9 million for the enterprise in fiscal 2025. Both parent companies guarantee certain debt and banking services for this joint venture.
- PT Panata Jaya Mandiri: A non-majority owned joint venture accounted for under the equity method, designed to support localized market penetration in Southeast Asia.
Other Investments (Including Minority / Portfolio Holdings)
The enterprise executes an acquisition and investment strategy targeted at acquiring advanced capabilities within the expanding bioprocessing and medical device arenas.
- Medica S.p.A. (49% Ownership): In August 2024, the enterprise invested €62.1 million ($67.9 million) to acquire a strategic non-controlling equity stake in this Italy-based leader in hollow fiber membrane filtration technology designed for medical and water purification applications. The enterprise holds a binding option to acquire the remaining 51% stake within a three-year window.
- Isolere Bio, Inc. (100% Ownership): Acquired in fiscal 2023, this Durham, North Carolina-based early-stage biotechnology firm developed the novel IsoTag™ reagents.
- Univercells Technologies (100% Ownership): Acquired in fiscal 2023 and headquartered in Belgium, this high-tech firm produces biomanufacturing solutions, including the scale-X™ bioreactor.
- Solaris Biotechnology S.r.l. (100% Ownership): Acquired in fiscal 2022 and based in Italy, Solaris custom-designs and manufactures bioprocessing equipment, including advanced bioreactors.
- Purilogics LLC (100% Ownership): Acquired in fiscal 2022, this South Carolina-based biotechnology firm developed the proprietary Purexa™ membrane chromatography platform.
Physical Properties
The physical infrastructure of the enterprise is modernized and distributed across six distinct continents to ensure supply chain resilience.
- Global Count: The physical footprint exceeds 150 total administrative, commercial, and technical locations worldwide.
- Manufacturing and Distribution: Exactly 77 distinct locations operate specifically as high-capacity manufacturing plants and distribution centers.
- Corporate Hubs: The primary corporate headquarters and central research facilities are rooted in Minneapolis, Minnesota. Additional administrative, engineering, and localized research nodes are positioned across the European, Asian, and Latin American regions.
- Asset Valuation: The net carrying value of physical property, plant structures, and equipment stands at $644.5 million, concentrated in heavy industrial machinery and precision automated equipment.
Founders
The industrial enterprise was officially founded in the year 1915. The century-long corporate legacy is characterized by an unbroken focus on advanced, technology-led industrial filtration solutions.
Investments and Capital Expenditure Plans
Capital allocation is disciplined by the executive team, balancing shareholder cash returns with funding for long-term technological development and global operational manufacturing efficiency.
- Capital Expenditures: The enterprise deployed $77.0 million in capital expenditures during fiscal 2025. These investments supported projects involving solvent recovery systems, new disk drive manufacturing technologies, and structural capacity for advanced air filtration media. Management expects fiscal 2026 capital expenditures to range between $65 million and $85 million.
- Research & Development: The organization invested $87.8 million in R&D during the fiscal year. This capital supports scientific laboratory research, facility testing costs, and the continuous development of material science capabilities.
- Future M&A Strategy: The enterprise maintains a strategy to accelerate long-term growth through targeted acquisitions in high-margin technical areas, specifically aiming to penetrate underserved industrial service markets and acquire early-stage bioprocessing technologies.
Shareholding Pattern
The corporate enterprise actively manages its equity structure, prioritizing continuous capital returns to its global shareholder base through consistent cash dividends and open-market stock repurchases.
- Shares Outstanding: As of September 12, 2025, there were 115,907,357 legal shares of common stock publicly outstanding in the market.
- Registered Stockholders: The public company reported 1,065 registered stockholders of record as of September 2025.
- Share Repurchase Execution: During fiscal 2025, the corporate treasury repurchased 4.9 million shares from the open market, returning $333.6 million in raw cash directly to shareholders.
- Repurchase Authorization: The Board of Directors authorized a 12.0 million share repurchase plan in November 2023, of which 5.9 million shares remain available for future open-market acquisition.
Future Strategy
The defined strategic corporate roadmap is defined by three primary growth pillars designed to expand the total addressable market and leverage foundational technological capabilities.
- Extend Market Access: The global enterprise is growing its commercial presence in the technical bioprocessing markets organically and through targeted acquisitions. Simultaneously, it is strengthening its engineering position in alternative power solutions through differentiated product innovation.
- Expand Technologies and Solutions: The company is globally implementing a “Create-Connect-Replace-Service” business model. This involves expanding connected digital service offerings, such as increasing connected cellular industrial machines, to capture recurring aftermarket service share.
- Pursue Strategic Acquisitions: Executive management is seeking to accelerate long-term growth by acquiring specialized firms with disruptive technologies in the bioprocessing space and expanding localized industrial service footprints.
Key Strengths
The competitive economic moat of the global enterprise is built upon a foundation of engineering technology, an integrated global logistical network, and a resilient financial business model.
- The Razor-to-Razorblade Model: The core financial architecture relies on generating predictable recurring aftermarket replacement sales. Within the Mobile Solutions segment, aftermarket replacement revenue constitutes 79% of total segment sales, insulating the company from the cyclicality of new heavy equipment manufacturing recessions.
- Technological Superiority: The advanced enterprise owns and defends a legal portfolio of over 3,100 global patents. Proprietary media like PowerCore®, Ultra-Web®, and Alpha-Web™ provide performance advantages that competitors struggle to replicate, allowing for premium pricing power in the market.
- Global Diversification: By maintaining a physical presence across distinct global geographies and different end markets, the corporate company successfully neutralizes localized economic recessions.
Key Challenges and Risks
Operating a complex high-technology manufacturing enterprise on a global scale involves navigating unpredictable macroeconomic risks.
- Macroeconomic and Geopolitical Instability: The global footprint directly exposes the enterprise to the rise of protectionist trade policies and punitive global tariff actions. Sustained tariff increases from China, Mexico, or the EU could adversely impact its integrated global supply chain and raw profitability.
- Disruptive Technological Shifts: The rapid global electrification of commercial vehicles and the regulatory transition toward alternative power solutions present a threat to traditional diesel engine filtration products. Failure to adapt to these green innovations could displace legacy revenue streams.
- Supply Chain and Material Costs: Heavy global operations are reliant on steel, specialized synthetic filter media, and petrochemical-based plastic products. The company often concentrates material sourcing from limited global suppliers; any sudden disruption or inflationary spike in these raw commodity materials could compress gross profit margins.
- M&A Execution Risks: Successfully integrating culturally different biotechnology firms poses operational challenges. This risk materialized in fiscal 2025, forcing a $62.0 million non-cash impairment charge due to slower-than-anticipated bioprocessing timelines.
- Cybersecurity Vulnerabilities: The digitally connected enterprise collects and stores sensitive intellectual property and proprietary technical data across complex global networks. A successful cyberattack could result in the destruction of proprietary data, defective manufacturing, and operational factory downtimes.
Conclusion and Strategic Outlook
Donaldson Company, Inc. concludes fiscal 2025 from a position of profound structural financial strength, having generated record total sales of $3.69 billion and impressive adjusted operating margins despite navigating an inflationary global macroeconomic environment. The enterprise has leveraged its defensive “razor-to-sell-razorblade” aftermarket model to drive recurring revenue through its vast aftermarket global channels, successfully insulating the corporate balance sheet from the cyclicality of its large OEM manufacturing partners.
Looking forward, the strategic outlook is focused on advanced technological evolution and global market expansion. While the $62.0 million accounting impairment charge within the Life Sciences segment highlights the inherent risks of acquiring early-stage bioprocessing technologies, the company’s continuous capital investments in next-generation solutions like the IsoTag™ reagents and Purexa™ membrane chromatography demonstrate a clear commitment to the high-margin biological sectors. Supported by a fortress balance sheet, a newly expanded $600 million corporate credit facility, and a commitment to shareholder capital returns via stock repurchases, the enterprise is optimized to advance complex filtration technologies for a cleaner, more efficient global economy.
FAQ Section
What is the core business model of the enterprise?
The enterprise fundamentally operates on a lucrative “razor-to-sell-razorblade” business model. It partners directly with OEMs to integrate its proprietary filtration systems into new capital equipment, which subsequently drives decades of recurring revenue through the continuous sale of replacement filters and maintenance services.
How much did the company generate in revenue for fiscal 2025?
The global organization achieved an all-time record high of $3,690.9 million in total consolidated net sales for the fiscal year 2025, driven by a $60.0 million volume increase and a $36.3 million benefit from disciplined pricing actions.
Why did the company record a $62 million impairment charge?
During the third quarter of fiscal 2025, the enterprise recorded a $62.0 million non-cash accounting impairment charge related to its recently acquired bioprocessing businesses. This was driven by lower-than-anticipated global capital spending in the broader bioprocessing market and extended drug development timelines affecting the valuation of the Univercells Technologies and Solaris units.
What geographic region generates the most global revenue?
The United States and Canada region is the largest corporate market, generating $1,632.3 million, which accounts for 44.2% of the total consolidated global net sales.
How is the company returning capital directly to shareholders?
The enterprise executes an aggressive capital return program. In fiscal 2025 alone, it returned $465 million directly to shareholders, combining $331.5 million in open-market share repurchases and distributing $131.9 million in direct cash dividend payments. Furthermore, the company has successfully increased its cash dividend for 30 consecutive years.
What technological threat do electric vehicles specifically pose to the corporate company?
The accelerated regulatory adoption of technologies providing zero-emission alternatives to traditional diesel engines, such as heavy-equipment electrification, poses a direct disruptive technological threat. This fundamental shift could reduce or permanently eliminate the global demand for legacy heavy fuel, lube, and traditional emission filtration products.
Official Site: donaldson.com
Source: Content on FirmsWorld.com is based on publicly available corporate filings, regulatory disclosures, annual reports, SEC 10-K filings, investor relations materials, and, where applicable, direct communications with the company.
